论文部分内容阅读
普萘洛尔是一种亲脂性非选择性β受体阻滞剂,在治疗婴幼儿血管瘤(IH)中取得了显著效果。然而,与其治疗相关的严重副作用也有报道。该文作者对2010年6月-2011年5月间采用阿替洛尔治疗的30例IH患者进行回顾分析,治疗效果采用视觉模拟评分(VAS)及血管瘤变化评分(HAS)进行评估。同时,对治疗出现的并发症进行记录。阿替洛尔组与2008
Propranolol, a lipophilic non-selective beta-blocker, has achieved significant results in the treatment of infantile hemangiomas (IH). However, serious side effects associated with their treatment have also been reported. The authors retrospectively reviewed 30 IH patients treated with atenolol between June 2010 and May 2011, and the treatment effect was assessed using visual analogue scale (VAS) and hemangiomas change score (HAS). At the same time, the complications of treatment were recorded. Atenolol group and 2008